NEWS - Apr 3, 2019 Gina DiGuglielmo Joins Relmada as Vice President and Head of Clinical Operations Read more
NEWS - Dec 12, 2018 Relmada Therapeutics Presents Clinical Data on Increased BDNF Plasma Levels in Subjects Treated with REL-1017 Read more
NEWS - Oct 2, 2018 Relmada Therapeutics to Present Clinical Data on the Effect of REL-1017 on BDNF Plasma Levels Read more
NEWS - Sep 18, 2018 Relmada Therapeutics Provides Enrollment Update in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder Read more
NEWS - Aug 9, 2018 Relmada Therapeutics Allowed Patent Application in China Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms Read more
NEWS - Jun 27, 2018 Relmada Therapeutics Inc. Announces First Patient Dosed in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder Read more
NEWS - Apr 3, 2018 Dr. Ottavio Vitolo Joins Relmada Therapeutics as Senior Vice President, Head of R&D and Chief Medical Officer Read more
NEWS - Jan 17, 2018 Relmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System Read more
NEWS - Jan 9, 2018 Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Europe Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms Read more
